Pregledni rad

Ovarian cancer – systemic therapy and the role of biomarkers

Tajana Silovski orcid.org/0000-0002-4699-5432 ; Medical Oncology Department, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Robert Šeparović orcid.org/0000-0002-4002-2699 ; Medical Oncology Department, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Ana Tečić Vuger orcid.org/0000-0003-2203-161X ; Medical Oncology Department, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Mirjana Pavlović orcid.org/0000-0002-9633-064X ; Medical Oncology Department, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia

Sažetak

Ovarian cancer is typically a disease susceptible to systemic antineoplastic treatment. Systemic antineoplastic therapy is indicated in almost all FIGO stages of ovarian cancer. In very early stage, well diff erentiated disease, benefi t gained with chemotherapy (CT) is no bigger than the 5-year survival rate per se, 90-98%, therefore CT is not indicated in these stages. Inall other stages, the systemic antineoplastic therapy is aplicable and desirable. It is based on platinum compounds, cisplatin and carboplatin, with addition of paclitaxel. For years, there was no advance in systemic chemotherapy treatment in ovarian cancer. The disease is treated as early, advanced and recurrent, and recurrent as platinum sensitive and platinum resistant disease, and this is how the drugs are being applied. Platinum basis, along with taxane partner is the basis and standard protocol, precisely carboplatinum – paclitaxel. There are also some other active agents, such as pegylated liposomal doxorubicin, topotecan etc. Beside the chemotherapy, a biological therapy holds an important spot in treating (epithelial) ovarian
cancer. Bevacizumab showed effi ciency and benefi t in platinum resistant and platinum sensitive recurrent disease, as well as in advanced, nonmetastatic and nonrecurrent disease. PARP inhibitor olaparib gained accelerated approval on the basis of significantly improved fast overall response rate and duration of response. It is yet to be shown, whether all the benefits of neoadjuvant approach, dose dense regimen, metronomic chemotherapy and intraperitoneal way of application of CT in treating ovarian cancer are being explored.

Ključne riječi

epithelial ovarian cancer; systemic treatment; carboplatinum; paclitaxel; bevacizumab; olaparib; FIGO stages; platinum - sensitive disease; platinum - resistant disease

Hrčak ID:

189823

URI

https://hrcak.srce.hr/189823

Datum izdavanja:

10.12.2015.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.647 *